Compare NVNI & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVNI | BFRG |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.7M |
| IPO Year | 2023 | 2022 |
| Metric | NVNI | BFRG |
|---|---|---|
| Price | $1.07 | $0.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.3K | ★ 121.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,670.00 |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $26.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.49 |
| 52 Week Low | $0.31 | $0.43 |
| 52 Week High | $4.94 | $2.04 |
| Indicator | NVNI | BFRG |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 41.62 |
| Support Level | $0.96 | $0.51 |
| Resistance Level | $1.31 | $0.69 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 28.55 | 35.58 |
Nvni Group Ltd, through its existing subsidiary companies, operates business-to-business software-as-a-service (B2B SaaS) products in Brazil, serving a diversified customer base of small and mid-sized enterprises across vertical markets. The Group's core business activity is providing a SaaS platform model focused on the software delivery method of cloud-based software applications to its customers. The Group generates revenues and profits from SaaS platform subscription services, data analytics services, set-up and other services. The Group has a single operating and reportable segment, multi-vertical SaaS solution model. The Group operates and generates revenue from Brazil.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.